<p><strong>Edgewise Therapeutics 纳斯达克股票代码: EWTX</strong> 单日上涨 50%，近期低点上涨 450% 并非偶然。其针对梗阻性肥厚型心肌病的新型口服选择性治疗在早期试验中表现出色。这一消息的重要性在于，肥厚型心肌病（简称 HCM）是 35 岁以下人群突发心脏相关死亡的主要原因。</p>
<p>HCM 是一种导致心肌增厚的遗传疾病，如今市值超过 12.5 亿美元且不断增长。目前尚无此类水平的治疗方法，医生主要依赖β受体阻滞剂和生活方式改变。如果获批，将使该公司从默默无闻一跃成为像 GLP-1 受体拮抗剂这样的畅销治疗药物，后者正在改变体重控制的方式。</p>
<p>获取 <strong>Edgewise Therapeutics</strong> 警报：</p>
<p>“对于患有梗阻性和非梗阻性 HCM 的患者仍存在未满足的需求，我们很高兴能参与正在评估一种新型治疗方法的 CIRRUS-HCM 试验，” 安贾利·T·欧文斯（Anjali T. Owens）博士在评论中表示，他是宾夕法尼亚大学遗传性心脏病中心的医学主任、医学副教授，也是 CIRRUS-HCM 的研究者。</p>
<h2>卖方利好指向 Edgewise Therapeutics 价格上涨</h2>
<p>经过多年的低迷，Edgewise Therapeutics 的股价今年开始回升，新闻报道变得积极，卖方兴趣重新被激发。价格目标下调的趋势结束，现在修订的目标将市场推向更高水平。</p>
<p>Marketbeat.com 报告的共识估计至少从 28 美元水平上涨 15%，但修订将导致高端范围。Wedbush 是少数在新闻发布后立即发出修订的公司之一，将目标价上调 42% 至 44 美元，接近今年早些时候由 Piper Sandler 设定的 48 美元的高点。这意味着这家医疗股票在未来十二个月内可能上涨 70%。</p>
<p>机构活动对该市场也持乐观态度。机构活动在第二季度激增至创纪录水平，并在第三季度保持稳健的步伐。结论是，机构、私募股权和风险投资拥有约 90% 的这家公司股票，内部人员拥有另外 4.5%，显示出他们对支持的高度信心。</p>
<h2>Edgewise Therapeutics 的空头挤压意味着未来的波动性</h2>
<p>空头头寸是股价飙升的一个因素。最近一份报告显示，空头头寸几乎达到 15%，足以引发挤压。由于 EDG-700 仍处于早期试验阶段，离获批还有很远，公司远未实现收入和利润，空头卖方可能会在更高水平重新调整头寸，并在未来几个季度对市场施加压力。好消息是，波动性和空头卖方意味着股价可能会下跌以重新测试坚实支撑。在这种情况下，股价可能会回落至 22 美元水平或更低，为投资者提供更有吸引力的入场点。</p>
<h2>Edgewise 不是一招鲜吃遍天</h2>
<p>Edgewise Therapeutics 在早期 1 期和 2 期试验中拥有吸引人但规模较小的候选药物管线。他们的目标是患有杜兴氏肌营养不良和贝克氏肌营养不良的个体，并迄今显示出积极结果。这些测试的下一批结果预计将于今年第四季度公布，可能为市场提供另一个催化剂。在运营方面，由于研究和缺乏收入，公司报告了亏损，但鉴于资产负债表，这些亏损是可以控制的。该公司拥有超过五亿美元的现金，足以维持当前水平的运营超过 15 个季度。</p>
<p>EWTX 的价格图表看起来不错。市场正在从上市后的低迷中恢复，并似乎处于全面逆转之中。价格走势得到日益增加的交易量支撑，因此有很高的概率会继续上涨。然而，投资者应该预计在宣布进一步发展之前，阻力将限制盈利接近历史高点。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png"/></p>
<p>→ 预测特朗普 2016 年胜选的人士：“为选举崩溃做好准备”（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5"/></p>
<h2>现在是否值得投资 1000 美元购买 Edgewise Therapeutics?</h2>
<p>在考虑投资 Edgewise Therapeutics 之前，您可能希望听听这个。</p>
<p>MarketBeat 持续追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户在更广泛市场注意之前购买的股票... 而 Edgewise Therapeutics 不在这个名单上。</p>
<p>尽管 Edgewise Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

EWTX

<p>Edgewise Therapeutics 的股价因其治疗梗阻性肥厚型心肌病（HCM）的早期试验结果积极而大涨 50%，同时也受到了空头头寸的平仓影响。该公司拥有前景看好的产品线和重要的机构支持，预计将面临波动，因为空头头寸仍然较高。分析师预测未来一年可能会有 70% 的上涨空间，但警告称股价可能会回落以测试支撑水平。拥有超过五亿现金的 Edgewise 处于良好的财务状况，可以在等待进一步试验结果的同时维持运营</p>

<p><strong>Edgewise Therapeutics NASDAQ: EWTX</strong> is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, selective treatment for obstructive hypertrophic cardiomyopathy did remarkably well in early trials. The news is important because hypertrophic cardiomyopathy or HCM for short, is the leading cause of sudden cardiac-related death in people under 35.</p>
<div class="lb-trans"><p><strong>Edgewise Therapeutics 纳斯达克股票代码: EWTX</strong> 单日上涨 50%，近期低点上涨 450% 并非偶然。其针对梗阻性肥厚型心肌病的新型口服选择性治疗在早期试验中表现出色。这一消息的重要性在于，肥厚型心肌病（简称 HCM）是 35 岁以下人群突发心脏相关死亡的主要原因。</p>
</div><p>HCM is a genetic disease causing thickening in the heart muscle, an industry worth more than $1.25 billion today and growing. There are no current treatments of this caliber, with doctors relying heavily on beta-blockers and lifestyle changes. If approved, it will rocket this company from obscurity into the ranks of blockbuster treatments like GLP-1 blockers, which are revolutionizing weight control.</p>
<div class="lb-trans"><p>HCM 是一种导致心肌增厚的遗传疾病，如今市值超过 12.5 亿美元且不断增长。目前尚无此类水平的治疗方法，医生主要依赖β受体阻滞剂和生活方式改变。如果获批，将使该公司从默默无闻一跃成为像 GLP-1 受体拮抗剂这样的畅销治疗药物，后者正在改变体重控制的方式。</p>
</div><p>Get <strong>Edgewise Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Edgewise Therapeutics</strong> 警报：</p>
</div><p>“There continues to be an unmet need for patients with obstructive and non-obstructive HCM, and we are excited to be part of the ongoing CIRRUS-HCM trial evaluating a novel treatment,” commented Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania and CIRRUS-HCM Investigator.</p>
<div class="lb-trans"><p>“对于患有梗阻性和非梗阻性 HCM 的患者仍存在未满足的需求，我们很高兴能参与正在评估一种新型治疗方法的 CIRRUS-HCM 试验，” 安贾利·T·欧文斯（Anjali T. Owens）博士在评论中表示，他是宾夕法尼亚大学遗传性心脏病中心的医学主任、医学副教授，也是 CIRRUS-HCM 的研究者。</p>
</div><h2>Sell-Side Interest Points to Higher Prices for Edgewise Therapeutics</h2>
<div class="lb-trans"><h2>卖方利好指向 Edgewise Therapeutics 价格上涨</h2>
</div><p>After years of wallowing, Edgewise Therapeutics's share price action began to perk up this year as the news stream turned positive and sell-side interest was reinvigorated. The trend of price target reductions ended, and now the revisions are leading the market higher.</p>
<div class="lb-trans"><p>经过多年的低迷，Edgewise Therapeutics 的股价今年开始回升，新闻报道变得积极，卖方兴趣重新被激发。价格目标下调的趋势结束，现在修订的目标将市场推向更高水平。</p>
</div><p>The consensus estimate reported by Marketbeat.com assumes at least a 15% upside from the $28 level, but revisions lead to the high-end range. Wedbush is among the few issuing revisions immediately after the news was released, raising its target by 42% to $44 and just shy of the high of $48. That was set by Piper Sandler earlier this year and implies a 70% upside is possible for this healthcare stock within the next twelve months.</p>
<div class="lb-trans"><p>Marketbeat.com 报告的共识估计至少从 28 美元水平上涨 15%，但修订将导致高端范围。Wedbush 是少数在新闻发布后立即发出修订的公司之一，将目标价上调 42% 至 44 美元，接近今年早些时候由 Piper Sandler 设定的 48 美元的高点。这意味着这家医疗股票在未来十二个月内可能上涨 70%。</p>
</div><p>Institutional activity is also bullish for this market. The institutional activity is robustly in favor of higher prices, surging to a record in Q2 and sustaining a solid pace in Q3. The takeaway is that institutions, private equity, and venture capital own about 90% of this stock and insiders another 4.5%, showing a high conviction in their support.</p>
<div class="lb-trans"><p>机构活动对该市场也持乐观态度。机构活动在第二季度激增至创纪录水平，并在第三季度保持稳健的步伐。结论是，机构、私募股权和风险投资拥有约 90% 的这家公司股票，内部人员拥有另外 4.5%，显示出他们对支持的高度信心。</p>
</div><h2>Short-Squeeze in Edgewise Therapeutics Means Volatility Ahead</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 的空头挤压意味着未来的波动性</h2>
</div><p>Short interest is a factor in the share price surge. The short interest was nearly 15% in the last report and sufficient for a squeeze. Because EDG-700 is still in early trials and far from approval, the company is far from revenue and profits, and the short-sellers will likely reposition at a higher level and weigh on the market over the next few quarters. The good news is that volatility and short-sellers mean the share price will likely decline to retest for solid support. In that scenario, the stock could retreat to the $22 level or lower, opening a more attractive entry for investors.</p>
<div class="lb-trans"><p>空头头寸是股价飙升的一个因素。最近一份报告显示，空头头寸几乎达到 15%，足以引发挤压。由于 EDG-700 仍处于早期试验阶段，离获批还有很远，公司远未实现收入和利润，空头卖方可能会在更高水平重新调整头寸，并在未来几个季度对市场施加压力。好消息是，波动性和空头卖方意味着股价可能会下跌以重新测试坚实支撑。在这种情况下，股价可能会回落至 22 美元水平或更低，为投资者提供更有吸引力的入场点。</p>
</div><h2>Edgewise is Not a One-Trick Pony</h2>
<div class="lb-trans"><h2>Edgewise 不是一招鲜吃遍天</h2>
</div><p>Edgewise Therapeutics has an attractive, if small, pipeline of candidates in early stage 1 and stage 2 trials. They target individuals with Duchenne and Becker muscular dystrophy and have shown positive results to date. The next batch of results from these tests is expected in Q4 of this year and may provide another catalyst for the market. Regarding operations, the company reports losses due to its research and lack of revenue, but the losses are manageable, given the balance sheet. The company has over half a billion in cash, sufficient to sustain operations at recent levels for over 15 quarters.</p>
<div class="lb-trans"><p>Edgewise Therapeutics 在早期 1 期和 2 期试验中拥有吸引人但规模较小的候选药物管线。他们的目标是患有杜兴氏肌营养不良和贝克氏肌营养不良的个体，并迄今显示出积极结果。这些测试的下一批结果预计将于今年第四季度公布，可能为市场提供另一个催化剂。在运营方面，由于研究和缺乏收入，公司报告了亏损，但鉴于资产负债表，这些亏损是可以控制的。该公司拥有超过五亿美元的现金，足以维持当前水平的运营超过 15 个季度。</p>
</div><p>The price chart of EWTX looks good. The market is recovering from its post-IPO blahs and appears to be in a full reversal. The price action is supported by increasingly high volume, so it has a high probability of continuing its advance. However, Investors should expect resistance to cap gains near the all-time highs until further developments are announced.</p>
<div class="lb-trans"><p>EWTX 的价格图表看起来不错。市场正在从上市后的低迷中恢复，并似乎处于全面逆转之中。价格走势得到日益增加的交易量支撑，因此有很高的概率会继续上涨。然而，投资者应该预计在宣布进一步发展之前，阻力将限制盈利接近历史高点。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png" alt="" original-src="https://www.marketbeat.com/logos/articles/med_20240919123339_chart-ewtx-9192024.png"/></p>
<p>→ Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 预测特朗普 2016 年胜选的人士：“为选举崩溃做好准备”（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzM5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9339&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Edgewise Therapeutics right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买 Edgewise Therapeutics?</h2>
</div><p>Before you consider Edgewise Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Edgewise Therapeutics 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 持续追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户在更广泛市场注意之前购买的股票... 而 Edgewise Therapeutics 不在这个名单上。</p>
</div><p>While Edgewise Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Edgewise Therapeutics 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Edgewise Therapeutics 股价飙升 50%：背后的关键原因